Herantis Pharma Plc
Company release, 30 October 2020 at 6 p.m. Eastern European Time
Herantis Pharma Plc (“Herantis”) announces Ingrid Heiman’s decision to step down from her role in Herantis’ Board of Directors effective immediately. Ingrid Heiman’s tenure in Herantis’ Board of Directors commenced in the extraordinary general meeting held in the spring of 2019.
“The Board and I wish to thank Ingrid for her work and commitment in the Board of Directors. With her participation, Herantis has pushed forward our mission of breaking the boundaries of standard therapeutic approaches with the goal of improving outcomes for patients,” commented Timo Veromaa, Herantis’ Chairman.
For more information, please contact:
Herantis Pharma Plc, Timo Veromaa, Chairman, telephone: +358 40 5739933
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.